Callyope, an AI-powered mental health monitoring company, secures €2.2 million in equity capital. The business is developing a speech-based platform for remote patient monitoring that will be utilised by individuals with bipolar disorder, major depression, and schizophrenia.
Together with No Label Ventures and business angels such as Thomas Clozel, co-founder and CEO of Owkin, and Adrien Montfort, co-founder and CTO of Sorare, the fundraising is co-led by 360 Capital and BPI Digital Venture.
With a focus on patient privacy, Callyope will use the funding to develop its machine learning technologies, expand its global network of research partners, and advancement its regulatory roadmap. Ultimately, the company hopes to become the cornerstone of accessible, customised mental health care.
Martin Denais, co-founder and CEO of Callyope shared: ” We have the conviction that our monitoring platform will become the foundation for affordable and evidence-based mental health care.”
Emanuele Levi, General Partner at 360 Capital, shared: “Mental health is one of the most pressing issues of our time. Prevalence among young people is skyrocketing while a shortage of caretakers is aggravating. Society needs scalable solutions for personalised care in mental health.”
Following the win of the Encephale 2023 prize, which brought Callyope recognition from French psychiatrists, the company is now working on research projects with prestigious mental hospitals to collect clinical datasets for the purpose of validating Callyope’s algorithms.
At Callyope, they think that through improving the objectivity and responsiveness of brain health monitoring, human-centered technology may enhance millions of people’s quality of life. They create remote patient monitoring systems to assist carers in identifying relapses and determining the best course of action.